Statement of Changes in Beneficial Ownership (4)

FORM 4

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL

OMB Number:

3235-0287

Estimated average burden
hours per response...

0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person * Bartushak Jaime	2. Issuer Name and Ticker or Trading Symbol Citius Pharmaceuticals, Inc. [ CTXR ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director                    _____ 10% Owner __X__ Officer (give title below)    _____ Other (specify below) Chief Financial Officer
(Last)          (First)          (Middle) C/O CITIUS PHARMACEUTICALS, INC., 11 COMMERCE DRIVE, FIRST FLOOR	3. Date of Earliest Transaction (MM/DD/YYYY) 10/8/2019
(Street) CRANFORD, NJ 07016 (City)        (State)        (Zip)	4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock								60353	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Purchase Common Stock) (1)	$0.67	10/8/2019		A		100000		(1)	10/8/2029	Common Stock	100000	$0	100000	D
Stock Option (Right to Purchase Common Stock) (2)	$1.62							(2)	9/4/2028	Common Stock	70000		70000	D
Stock Option (Right to Purchase Common Stock) (3)	$3.45							(3)	9/15/2027	Common Stock	25000		25000	D
Stock Option (Right to Purchase Common Stock) (4)	$10.50							(4)	7/6/2026	Common Stock	48267		48267	D

Explanation of Responses:
(1)	The options were granted on October 8, 2019. The options will vest 1/3 on each of the one-year, two-year and three-year anniversary of the Vesting Commencement Date, provided that the Optionee provides Continuous Service to the Company on each such vesting date.
(2)	One-third of the shares of the Company's common stock underlying the grant vest on each of the one-year, two-year and three-year anniversary of the Vesting Commencement Date, September 4, 2018, provided that the Optionee provides Continuous Service to the Company on each such vesting date.
(3)	On September 15, 2017 the Reporting Person was granted a ten-year option to purchase 25,000 shares of common stock at an exercise price of $3.45 per share. The options vest as follows: 8,333 shares vest on September 13, 2018, and then 694 shares per month for the next 24 months.
(4)	On July 6, 2016 the Reporting Person was granted a ten-year option to purchase 48,267 shares of common stock at an exercise price of $10.50 per share. The options vest as follows: 16,089 shares vest on July 7, 2017, and then 1,341 shares per month for the next 24 months.

Reporting Owners
Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
Bartushak Jaime C/O CITIUS PHARMACEUTICALS, INC. 11 COMMERCE DRIVE, FIRST FLOOR CRANFORD, NJ 07016			Chief Financial Officer

Signatures
/s/ Alexander M. Donaldson, by power of attorney		10/10/2019
**Signature of Reporting Person		Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*	If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:	File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

1 Year Citius Pharmaceuticals Chart

1 Month Citius Pharmaceuticals Chart